GlassScriptPhysician profile
Kelcie D Cobb
NPI 1184145567
$1,767.70
in general payments reported to CMS, 2019-2025
26 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $363 · 2023: $409 · 2024: $275 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,093.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,092.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $439.00 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $279.43 | 2021-2025 | |
| Lilly USA, LLC | $133.16 | 2021-2025 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $126.50 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $89.79 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.73 | 2021-2023 | Trintellix |
| Vanda Pharmaceuticals INC. | $71.33 | 2024-2025 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.50 | 2021-2024 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $57.75 | 2021 | |
| Merck Sharp & Dohme LLC | $48.66 | 2021-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $38.32 | 2021-2023 | Breztri |
| Abbvie INC. | $38.10 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $34.91 | 2023 | |
| Dynavax Technologies Corporation | $34.29 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $33.40 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.59 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.19 | 2024 | Gvoke Hypopen |
| Astellas Pharma US INC | $23.92 | 2025 | Veozah |
| Boston Scientific Corporation | $21.67 | 2024 | Bodyguardian |
| Organon LLC | $19.91 | 2025 | Nexplanon |
| Alnylam Pharmaceuticals INC. | $19.40 | 2025 | Givlaari |
| Janssen Pharmaceuticals, INC | $16.58 | 2025 | Spravato |
| Cranial Technologies, INC | $16.18 | 2025 | Doc Band |
| Amarin Pharma, INC. | $15.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.83 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelcie Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.